These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36739246)

  • 1. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study.
    Bajo MA; Ríos-Moreno F; Arenas MD; Devesa-Such RJ; Molina-Higueras MJ; Delgado M; Molina P; García-Fernández N; Martin-Malo A; Peiró-Jordán R; Cannata-Andia J; Martín-De Francisco ÁL;
    Nefrologia (Engl Ed); 2022; 42(5):594-606. PubMed ID: 36739246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study.
    Vervloet MG; Boletis IN; de Francisco ALM; Kalra PA; Ketteler M; Messa P; Stauss-Grabo M; Derlet A; Walpen S; Perrin A; Ficociello LH; Rottembourg J; Wanner C; Cannata-Andía JB; Fouque D
    Clin Kidney J; 2021 Jul; 14(7):1770-1779. PubMed ID: 34221384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
    Sprague SM; Ketteler M; Covic AC; Floege J; Rakov V; Walpen S; Rastogi A
    Hemodial Int; 2018 Oct; 22(4):480-491. PubMed ID: 29656600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
    Greenbaum LA; Jeck N; Klaus G; Fila M; Stoica C; Fathallah-Shaykh S; Paredes A; Wickman L; Nelson R; Swinford RD; Abitbol CL; Balgradean M; Jankauskiene A; Perrin A; Enoiu M; Ahn SY
    Pediatr Nephrol; 2021 May; 36(5):1233-1244. PubMed ID: 33106892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.
    Liu J; Zuo L; Walpen S; Bernard L; Marty M; Enoiu M
    Nephron; 2024; 148(1):22-33. PubMed ID: 37473746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
    Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
    Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to improve adherence the captors of phosphorus on hemodialysis: Experience in real life with sucroferric oxyhydroxide.
    Arenas Jiménez MD; Navarro González JF
    Nefrologia (Engl Ed); 2020; 40(6):640-646. PubMed ID: 32564940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Covic AC; Floege J; Ketteler M; Sprague SM; Lisk L; Rakov V; Rastogi A
    Nephrol Dial Transplant; 2017 Aug; 32(8):1330-1338. PubMed ID: 27342579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
    Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
    Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
    J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease. FOSFASTUR study.
    Sanchez-Alvarez JE; Astudillo Cortes E; Seras Mozas M; García Castro R; Hidalgo Ordoñez CM; Andrade López AC; Ulloa Clavijo C; Gallardo Pérez A; Rodríguez Suárez C
    Nefrologia (Engl Ed); 2021; 41(1):45-52. PubMed ID: 33239181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.